Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Multicentre Aneurysm Screening Study Group Correspondence to:
M J Buxton Health Economics Research Group, Brunel University,
Uxbridge, Middlesex UB8 3PH martin.buxton{at}brunel.ac.uk
Objective:
To assess the cost effectiveness of
ultrasound screening for abdominal aortic aneurysms.
What is already known on this topic
There is uncertainty about the cost effectiveness of routine screening,
with widely varying estimates What this study adds
The adjusted net cost per patient was £63.39 and per life year gained
was £28 400 The projected cost per life year gained after 10 years was £8000,
which is substantially lower than the perceived NHS threshold
value
Design:
Primary analysis: four year cost
effectiveness analysis based directly on results from a randomised
controlled trial in which patients were individually allocated to
invitation to ultrasound screening (intervention) or to a control group
not offered screening. Secondary analysis: projection of the data, based on conservative assumptions, to indicate likely cost
effectiveness at 10 years.
Setting:
Four centres in the United Kingdom.
Screening delivered in primary care settings with follow up and surgery offered in the main hospitals
Participants:
Population based sample of 67 800 men
aged 65-74 years.
Main outcome measures:
Mortality from and costs
(screening, follow up, elective and emergency surgery) related to
abdominal aortic aneurysm; cost per life year gained.
Results:
Over four years there were 47 fewer deaths related to abdominal aortic aneurysms in the screening group than in
the control group, but the additional costs incurred were £2.2m. After
adjustment for censoring and discounted at 6% the mean additional cost
of the screening programme was £63.39 ($97.77,
100.48) (95% confidence interval £53.31 to £73.48) per patient. The hazard ratio
for abdominal aortic aneurysm was 0.58 (0.42 to 0.78). Over four years
the mean incremental cost effectiveness ratio for screening was
£28 400 (£15 000 to £146 000) per life year gained, equivalent to
about £36 000 per quality adjusted life year. After 10 years this
figure is estimated to fall to around £8000 per life year gained.
Conclusions:
Even at four years the cost
effectiveness of screening for abdominal aortic aneurysms is at the
margin of acceptability according to current NHS thresholds. Over a
longer period the cost effectiveness will improve substantially, the predicted ratio at 10 years falling to around a quarter of the four
year figure.
Small trials have suggested that an ultrasound screening programme to
detect abdominal aortic aneurysms in older men may be
effective
A cost effectiveness analysis of data from a large randomised trial
with follow up over four years showed 47 fewer deaths and additional
costs of £2.2m in the group invited to screening
© BMJ 2002
Read all Rapid Responses